Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
The best defence is a good offence. This adage, often applied to sports or military strategies, suggests that attacking one's opponent offers the greatest protection. Researchers and clinicians are taking this approach to fight cancer — developing powerful new therapies that seek out and kill cancer cells.
One such approach is immune therapy: it works by boosting the number and activity of tumour-infiltrating lymphocytes (TILs), immune cells that go on the offensive by migrating into tumours to target and destroy them. Although this strategy holds promise, challenges remain because certain tumours have developed defence mechanisms that block TIL activity.
These tumours, however, are no match for
Dr. Pamela Ohashi. She is a pioneer in figuring out how the immune system interacts with cancer in order to develop new immune therapies.
an article published in the prestigious journal
Nature Medicine, Dr. Ohashi and her research team, including Dr. Sarah Crome, revealed that an internal battle may be going on: they found that certain ovarian tumours contain other immune cells, called regulatory innate lymphoid cells (ILCregs), that block the activity of cancer-fighting TILs. The ILCregs did this in two ways: they reduced the ability of TILs to grow and multiply, and altered the ability of the TILs to attack cancer cells.
The team also found that the tumours from some patients contained ILCregs, while those from others did not, suggesting that some tumours may be able to attract or promote growth of ILCregs.
"By looking at tumour biology from this different perspective, we have a better understanding of the barriers that prevent a strong immune response," explains Dr. Ohashi. "Our research reveals a promising new strategy to develop combined therapies that simultaneously target ILCregs while promoting TIL growth and function — delivering a
stronger 'one-two punch' against the disease."
Building on these findings, her team is now developing a test to identify ILCregs in patients, which may help predict whether the patient will respond to immune therapy.
"This knowledge would help doctors and patients make more informed medical decisions, personalize cancer treatment and ultimately improve the effectiveness of immune therapies," Dr. Ohashi says.
Supported by the Canadian Institutes of Health Research, the Cancer Research Institute/Irvington Institute, the Canada Foundation for Innovation, the Ontario Ministry of Research, Innovation and Science, the Alexander von Humboldt Foundation, the German Research Council, the National Institutes of Health, the Parker Institute for Cancer Immunotherapy and The Princess Margaret Cancer Foundation.